ADMA

ADMA Biologics Inc.

Price

$10.49

return (12m)

p/e

12.58

p/bv

5.33

DIVIDEND YIELD

0.00%

ADMA price

ADMA Biologics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ADMA

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals ADMA

Valuation

P/E

12.58

Sector -4.15

Industry -4.15

P/BV

5.33

Sector 2.06

Industry 2.06

P/Revenue (PSR)

4.08

Sector -4.16

Industry -4.16

EV/EBITDA

34.97

Sector -241.86

Industry -241.86

EV/EBIT

36.06

Sector -671.75

Industry -671.75

P/EBITDA

9.39

Sector -4.30

Industry -4.30

P/EBIT

9.74

Sector -4.35

Industry -4.35

P/Total Assets

3.13

Sector 1.46

Industry 1.46

P/Net Current Assets

8.80

Sector -12.67

Industry -12.67

P/Working Capital

4.75

Sector -12.58

Industry -12.58

EPS

0.70

Sector -2.19

Industry -2.19

BVPS

1.65

Sector 1.92

Industry 1.92

Efficiency

Gross Margin

61.28%

Sector 36.44%

Industry 36.44%

EBITDA Margin

53.34%

Sector -16,748.51%

Industry -16,748.51%

EBIT Margin

51.73%

Sector -4,256,846.44%

Industry -4,256,846.44%

Operating Margin

40.57%

Sector -38.78%

Industry -38.78%

Net Profit Margins

32.43%

Sector -39.93%

Industry -39.93%

Asset Turnover

0.17

Sector 0.03

Industry 0.03

Profitability

ROE

42.37%

Sector -67.01%

Industry -67.01%

ROA

24.86%

Sector -66.28%

Industry -66.28%

ROIC

34.00%

Sector -2,917.75%

Industry -2,917.75%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

6.95

Sector 2.90

Industry 2.90

Net Debt / EBITDA

0.91

Sector -12,252,405.04

Industry -12,252,405.04

Net Debt / EBIT

0.94

Sector -3.79

Industry -3.79

Net Debt / Equity

0.14

Sector -33,290.93

Industry -33,290.93

Gross Debt / Equity

0.50

Sector 0.00

Industry 0.00

Equity/Assets

0.59

Sector 0.42

Industry 0.42

Liabilities/Assets

0.41

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

44.50%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF ADMA Biologics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$10.49

Fair Value

$5.10

Upside Return potential.

-51.40%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ADMA

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ADMA ADMA Biologics Inc.	$10.49	-45.93%	0.00%	12.58	5.33	42.37%	32.43%
AZN AstraZeneca PLC	$204.64	53.45%	1.89%	25.20	5.52	21.93%	17.19%
JNJ Johnson & Johnson	$240.16	62.69%	2.08%	28.83	0.00	-%	21.48%
NBIX Neurocrine Biosciences Inc.	$130.81	43.95%	0.00%	25.46	5.00	19.62%	21.55%
ABEO Abeona Therapeutics Inc.	$5.19	12.83%	0.00%	6.09	2.78	45.63%	100.00%
PFE Pfizer Inc.	$27.11	32.71%	6.97%	18.76	1.55	8.29%	11.83%
ABBV AbbVie Inc.	$210.26	25.08%	2.61%	125.53	-69.01	-54.98%	5.79%
ABUS Arbutus Biopharma Corporation	$4.35	38.54%	0.00%	5.66	3.50	61.77%	83.94%
ACAD ACADIA Pharmaceuticals Inc.	$22.02	51.03%	0.00%	11.55	3.48	30.10%	34.30%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ADMA Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT ADMA Biologics

ADMA Biologics Inc.

Average Investor10 user rating

4.0 (0 people)

States of America

22 years

Founded: 2004

2013

Time since IPO - 13 years

407

Employees

ADMA Biologics Inc. (States of America) is listed on the Nasdaq and has a market capitalization of $2.08 billion, with shareholders equity totaling $390.32 million.

The company employs approximately 407 people and operates in the Healthcare sector, within the Biotecnologia industry.

Over the past 12 months, ADMA Biologics Inc. reported $509.85 million in revenue, generating net income of $165.36 million.

Key financial metrics include a P/E ratio of 12.58, a price-to-book (P/B) ratio of 5.33, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ADMA.

Market cap

$2.08 billion

Net worth

$390.32 million

$390,320,000.00

Assets

$665.18 million

$665,180,000.00

Total Shares Outstanding

236.00 million

236,000,000

Average Daily Trading Volume

$4.49 million

$4,493,790.00

Sector

Healthcare

Industry

Biotecnologia

ADMA

ADMA revenue and profits

Financial Results ADMA

DRAG THE FRAME TO SEE MORE DATA

ADMA cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$862.96 22,54% (12M)

P/E

21.66

0.39%

ROE

-570.98%

P/BV

-123.68

CAH - Cardinal Health

$214.95 38,63% (12M)

P/E

34.90

0.89%

ROE

-58.20%

P/BV

-20.31

JNJ - Johnson & Johnson

$240.16 47,25% (12M)

P/E

28.83

2.08%

ROE

P/BV

0.00

MRK - Merck & Co.

$119.96 46,43% (12M)

P/E

35.53

2.62%

ROE

19.45%

P/BV

6.91

AZN - AstraZeneca

$204.64 40,78% (12M)

P/E

25.20

1.89%

ROE

21.93%

P/BV

5.52

ABBV - AbbVie

$210.26 15,08% (12M)

P/E

125.53

2.61%

ROE

-54.98%

P/BV

-69.01

NVO - Novo Nordisk

$39.32 --40,26% (12M)

P/E

11.83

3.68%

ROE

60.40%

P/BV

7.14